Endocrine Disruptors

Chemical safety is paramount
Endocrine disruptors (EDs) are currently the main focus of the discussions on man-made chemicals. The European Commission is now expected to set criteria to identify endocrine disrupting chemicals by the summer of 2016. For 15 years, world-wide, science has advanced in this field, significantly improving the chemical framework in Europe. Meanwhile, more questions and concerns about the hormonal effect of substances have been raised. It is the industry’s duty to take an active part in this debate and to share its views on how best to ensure safety; i.e. to identify and regulate endocrine disruptors of concern.

Identifying endocrine disruptors: Do not judge a book by its cover
PlasticsEurope supports criteria for identification of endocrine disruptors based on the WHO definition of EDs. However, for the definition to be effective in a regulatory context, more elements (such as potency) are requested to identify substances which can produce adverse effects directly linked to ED mode of action. Other elements such as severity, (ir)reversibility and selectivity must also be included. The full hazard characterisation will allow differentiation between substances identified for which regulatory measures are needed and other substances of low potency which do not warrant a high concern. It is therefore crucial to adopt such an approach in order to best identify and regulate suspected endocrine disrupting substances.

Regulating endocrine disruptors: The dose still makes the difference
Certain natural substances can interact with the endocrine system but would only cause adverse effects at doses that are never reached in real life. Below these doses, these substances can be consumed without concern. The same applies for synthetic substances which have similar effects: for these substances, safe doses are set far below the level at which any effect can be measured. Nevertheless, some scientists claim that there are no thresholds below which an endocrine disrupting substance can be considered safe. These claims remain hypothetical since reported low dose effects could not be reproduced or confirmed by more comprehensive studies. Most conclusive scientific results so far show that thresholds can in principle be set for EDs.

Key recommendations:

1. **Distinguish endocrine disruptors (EDs) from endocrine active substances**
   A substance should not be identified as an ED only because it interacts with or impacts the hormonal system. An ED is a substance which causes adverse effects via that system. Some stakeholders propose categories to distinguish one type of “endocrine disruptors” from another (confirmed and suspected). This approach fails to achieve the first priority which is to identify confirmed EDs for applying existing regulatory provisions.

2. **Make sure regulation considers the characteristics of adverse effects**
   In order to identify EDs of concern, regulation must also take into account the characteristics of the adverse effects that were observed during testing. Is the effect powerful, severe, or irreversible? Is there a link between the substance and the adverse effect? If these considerations were to be left out, it would be difficult to differentiate substances for which regulation is needed from those with the same low endocrine potency as carrots.

3. **Allow science to set thresholds for endocrine disruptors**
   Conclusive research shows that thresholds can be set for EDs. For this purpose, each substance needs to be considered on a case by case basis. In most cases a threshold can be set. Exceptionally, it may not be possible. In any case, regulation should not pre-empt the outcome of the assessment.